Diseases /
Prolymphocytic Leukemia
Back to Diseases List
Associated Genetic Biomarkers
Overview
NCI Definition: A mature B- or T- cell leukemia with progressive clinical course. It is characterized by the presence of medium-sized lymphocytes with visible nucleoli (prolymphocytes) in the peripheral blood, bone marrow, and spleen. [1]
Prolymphocytic leukemias most frequently harbor alterations in JAK3, ATM, TP53, STAT5B, and STAG2 [2].
JAK3 Mutation, ATM Mutation, TP53 c.217-c.1178 Missense, TP53 Mutation, and TP53 Missense are the most common alterations in prolymphocytic leukemia [2].
Clinical Trials
Significant Genes in Prolymphocytic Leukemia
Disease Details
References
1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].
2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.